Answers are grounded in this paper and cite their sources.
This Viewpoint discusses the controversy surrounding the FDA’s efforts to withdraw Makena from the market and the broader implications for the accelerated approval pathway.
No takes yet. Share an insight, caveat, or question.
Aaron et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: